Artwork

Player FM - Internet Radio Done Right
Checked 19h ago
Lagt till five år sedan
Innehåll tillhandahållet av Dr Neil Love. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr Neil Love eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
icon Daily Deals

Paroxysmal Nocturnal Hemoglobinuria | Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria

1:46:18
 
Dela
 

Manage episode 453660545 series 2530615
Innehåll tillhandahållet av Dr Neil Love. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr Neil Love eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

  • Diagnosis of and myths and misperceptions about PNH (0:00)

Overview — Biology and Pathophysiology

  • Role of complement activation in PNH; classification and clinical presentation (7:00)
  • PNH treatments and their complement targets (21:37)

Current Management Approaches

  • Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
  • Timing for initiation of treatment for PNH (32:08)
  • Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
  • Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
  • Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
  • Activity and safety of and clinical experience with crovalimab (53:03)
  • Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

  • Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
  • Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
  • Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
  • Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

CME information and select publications

  continue reading

1413 episoder

Artwork
iconDela
 
Manage episode 453660545 series 2530615
Innehåll tillhandahållet av Dr Neil Love. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Dr Neil Love eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

  • Diagnosis of and myths and misperceptions about PNH (0:00)

Overview — Biology and Pathophysiology

  • Role of complement activation in PNH; classification and clinical presentation (7:00)
  • PNH treatments and their complement targets (21:37)

Current Management Approaches

  • Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
  • Timing for initiation of treatment for PNH (32:08)
  • Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
  • Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
  • Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
  • Activity and safety of and clinical experience with crovalimab (53:03)
  • Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

  • Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
  • Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
  • Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
  • Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

CME information and select publications

  continue reading

1413 episoder

Alla avsnitt

×
 
Loading …

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

 

icon Daily Deals
icon Daily Deals
icon Daily Deals

Snabbguide

Lyssna på det här programmet medan du utforskar
Spela